SWOG clinical trial number
S1800A

A PHASE II RANDOMIZED STUDY OF RAMUCIRUMAB PLUS MK3475 (PEMBROLIZUMAB) VERSUS STANDARD OF CARE FOR PATIENTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP NON-MATCHED SUB-STUDY)

Open
Accrual
5%
Abbreviated Title
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study
Status Notes
S1800A will open to accrual May 17, 2019, effective 11:00 am PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Activated
05/17/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Lung Cancer

Treatment

Rucaparib

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-8241

Treatment of Advanced Non-Small Cell Lung Cancer: PVp Versus PVpM Versus PVe Versus PVeMI Versus FOMi/CAP

Research Committee(s)
Lung Cancer
Activated
12/23/1982
Closed
11/01/1984
Closed
Phase
III
Published